PMCB

PharmaCyte Biotech Inc

Add to Watchlist

Advanced Chart

0.790

-0.061(-7.165%)1D

Line

Candle

YTD

High

0.8786

Open

0.840

VWAP

0.81

Vol

57.45K

Mkt Cap

5.37M

Low

0.7813

Amount

46.71K

EV/EBITDA(TTM)

Total Shares

8.45M

-8.89M

EV/OCF(TTM)

P/S(TTM)

PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2023Q4

-0.090

+50%

Estimates Revision

Stock Price

Go Down

-11.10%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for PharmaCyte Biotech Inc (PMCB.O) is -2.24, compared to its 5-year average forward P/E of -9.63. For a more detailed relative valuation and DCF analysis to assess PharmaCyte Biotech Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.63

Current PE

-2.24

Overvalued PE

5.82

Undervalued PE

-25.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.01

Current PS

0.85

Overvalued PS

0.10

Undervalued PS

-0.08

Financials

Annual

Quarterly

FY2026Q1

0.00

Total Revenue

FY2026Q1

YoY :

-33.15%

-848.31K

Operating Profit

FY2026Q1

YoY :

-135.69%

-8.36M

Net Income after Tax

FY2026Q1

YoY :

-164.74%

-1.23

EPS - Diluted

FY2026Q1

YoY :

+434.15%

-1.99M

Free Cash Flow

FY2026Q1

N/A

ROIC

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

PMCB News & Events

Events Timeline

2025-09-02 (ET)

2025-09-02

09:26:32

PharmaCyte Biotech Boosts Investment in TNF Pharmaceuticals by $3 Million

News

8.5

09-02Newsfilter

PharmaCyte Biotech, Inc. Expands Investment in TNF Pharmaceuticals Following New License for Innovative Light Speed Computing Platform for Cryptocurrency Use

8.5

08-18Newsfilter

PharmaCyte Biotech, Inc. Secures $7 Million in Funding from Current Investors